报 告 人：Michael J. Shapiro 诺华制药 研究员
报告题目1：“Fragment Based Drug Design-Back to the Future”
题目 2：“Cyclic Peptide Drug Design- What we know and Don't Know”
报告时间：11月14日 周一 上午10：00
报告地点：温州大学南校区杏吧视频 11B-523
主要学习及工作简历：
Senior Director 2015 –current        Novartis
Director of Analytical Chemistry 9/2010 – 2016
• Novartis Leading Scientist (First Round)
• Research Fellow with over 25 years of pharmaceutical drug discovery experience.
• Successfully worked with teams in putting compounds from discovery to market.
• Developed novel techniques, applications and concepts for drug discovery.
• Revitalized and directed the Analytical Research Technology laboratories- Coining the title  “ART of Chemistry”
• Developed novel tools for molecular property evaluation.
• Initiated and developed a novel method of structure determination for small molecules using quantitative NOE an RDC experiments.
• 10 years of Fragment Based Drug design Experience
• Initiated and supported the creation of the Fragment Based Drug Design at Novartis and Lilly; championed the use of Fragments in drug design leading to vital contributions to IKK?, MMP-13, DPPIV, BACE, iGlur,  ER??and others.